What are Direct thrombin inhibitor drugs?

Direct thrombin inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Thrombin (serine protease)). 2 are currently marketed, with 4 more in clinical development.

What are the marketed Direct thrombin inhibitor drugs?

Marketed Direct thrombin inhibitor drugs include Pradaxa, r-Hirudin.

Direct thrombin inhibitor

2 marketed 3 in Phase 3 1 in Phase 2

This page covers all Direct thrombin inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thrombin (serine protease), Thrombin (Factor IIa), Factor IIa (Thrombin).

Targets

Thrombin (serine protease) · Thrombin (Factor IIa) · Factor IIa (Thrombin)

Marketed (2)

Pradaxa · Boehringer Ingelheim · Cardiovascular
Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development.
r-Hirudin · MinaPharm Pharmaceuticals · Cardiovascular
r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin.

Phase 3 pipeline (3)

BAY86-5016, SH P00331F · Bayer · Cardiovascular
BAY86-5016 is a Factor IIa (thrombin) inhibitor that directly blocks the active site of thrombin to prevent blood clot formation.
FOY-305 · Ono Pharmaceutical Co. Ltd · Cardiovascular
FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.
Angiomax (bivalirudin) · The Medicines Company · Cardiovascular
Bivalirudin is a direct thrombin inhibitor that binds to and blocks thrombin, preventing blood clot formation.

Phase 2 pipeline (1)

BAY 77-1931 · Bayer · Cardiovascular
BAY 77-1931 is a direct thrombin inhibitor that blocks the active site of thrombin to prevent blood clot formation.